![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Fuzeon Plus Active Protease Inhibitor Shows Maximal HIV Suppression
Fuzeon Plus Active Protease Inhibitor Shows Maximal HIV Suppression
Patients previously treated with three classes of antiretrovirals can achieve maximal viral suppression when starting a regimen of Fuzeon in combination with an active boosted protease inhibitor and other anti-HIV drugs, according to new study data.
These new studies add to the growing body of evidence that support a powerful treatment strategy for treatment-experienced patients -- building upon findings from the Fuzeon (enfuvirtide) pivotal trials, TORO-1 and TORO-2. Co-developed by Roche and Trimeris, Fuzeon is the first and only fusion inhibitor available for the treatment of HIV.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct